Nucleate Singapore

🔐 Nucleate Ignite TD Workshop — Day 3: Cracking the Code on Biotech IP 💭 What exactly is intellectual property, and why is it the backbone of biotech startups? In our third session, we explored the fundamentals of IP strategy — learning how to protect innovation, navigate legal landscapes, and build long-term value from Day 1. From identifying what qualifies as IP to drafting strong patents, participants gained essential tools every biotech founder needs. 💼 Key Takeaways: • What counts as IP in biotech • Patent processes, timelines, and costs • FTO (Freedom to Operate) & IP landscaping • Regional filing strategies (US, EU, Singapore) • When and how to work with IP lawyers • Embedding IP into your startup’s value proposition A huge thank you to our speakers for simplifying a complex topic and highlighting how smart IP strategies drive both innovation and investment. 📢 Follow Nucleate Singapore for more updates and upcoming sessions. #NucleateIgnite #BiotechIP #StartupStrategy #IntellectualProperty #BiotechInnovation #TranslationalScience #IPStrategy #BiotechFounders #NucleateSingapore #MewburnEllis

🏆 Congratulations to the QDX Hackathon Champions! A big round of applause to all the brilliant minds who brought their A-game to the competition and pushed the limits of innovation! 💡🚀 🥇 1st Place – Protein Shake aditya vikram sinha(https://lnkd.in/g7zQ4bim) Arnav Jhajharia(https://lnkd.in/gpzzJVPh) Aarav Bindawala(https://lnkd.in/gnHcXDsS) Shubham Choudhary(https://lnkd.in/gWGaXPZw) 🥈 2nd Place – Fivefold Shamieraah J.(https://lnkd.in/gP63mtgX) Amelia Chng(https://lnkd.in/gTDc7T6p) Eunice Tan(https://lnkd.in/gSh7pwnz) Tom Syme(https://lnkd.in/gmCRBAjJ) Joshua Lam(https://lnkd.in/gb6kC6z6) 🥉 3rd Place – Bruteforcer Wei Jie Thor(https://lnkd.in/gbCmgiHZ) Lim Jian Heng(https://lnkd.in/g9Dtqjux) Tjandy Putra(https://lnkd.in/gnJ2ZKM2) ✨ Honourable Mentions ⏱ Most Compute Time Used: Derek Island – 11,928 minutes! 🔁 Most Submissions: Breaking Binds – 673 attempts! 🔥 Most Active Community Member: @adityavikramsinha Incredible work by all participants — your creativity, collaboration, and determination made this an unforgettable experience. We’re excited to see where you go next! 🔗 Learn more about Rush, the AI-assisted life science research platform here: https://lnkd.in/gSEJtcK7 📢 Follow Nucleate Singapore on LinkedIn for upcoming events, resources, and community opportunities! #HackathonWinners #Innovation #TechExcellence #BiotechFuture #QDXHackathon #NucleateSingapore

🚨 Last Call! Don’t Miss Out on the PDA Day 2025! 🚨 Secure your spot at one of the most valuable career development events for postdocs, graduate students, and research staff in Singapore! 🔗 https://lnkd.in/gaSzy5u2. This full-day event is packed with insightful sessions tailored to help you navigate your career journey — whether you're aiming for academia, education, biotech, or consulting. 📆 Check out the full programme: 🔗 https://lnkd.in/djKFk7ai 💡This is your chance to access expert insights, real career stories, actionable strategies, and meaningful connections — all in one day! Jointly organized by NUS Yong Loo Lin School of Medicine’s Office of Postdoctoral Affairs (#OPA) and Postdoctoral Association (#PDA), in partnership with NUS Medical Science Alliance. See our past events: https://lnkd.in/g4CR5yUb | Join NUS Postgraduate Students & Postdoc Telegram Group: https://lnkd.in/g2ih4p2Z | Join PDA 2025/2026 Committee: https://lnkd.in/gWjRqmsW Assistant Dean, Division of Graduate Studies; Director, NUS Yong Loo Lin School of Medicine Office of Postdoctoral Affairs, Dr Alan Prem Kumar, Ph.D. OPA Leads Hiu Yan (Maggie) LAM, Ph.D. | Bibek Dutta | Grishma Rane | Shuo Deng | govinda lenka | Noof Abdullah Saad Shaif | Debashis Majee, PhD | Vanja Cnops | Neelima Gupta | Hataitip Tasena, PhD #CareerDevelopment #Postdocs #PhD #Networking #PhDCareers

🔬The Nucleate Artery: Drug delivery using bacteria, and new ways to remove harmful fat build ups 📰 This month’s issue is packed with biotech breakthroughs that push the boundaries of how we think about drug delivery, joint aging, brain health, and metabolic disease. 🦠 Nose-to-Brain Drug Delivery Using Engineered Bacteria: NUS scientists engineered Lactobacillus plantarum to secrete appetite-suppressing hormones directly into the brain, showing real potential for treating obesity and other neurological diseases. 🧓 Protecting Aging Joints from Arthritis: Researchers at A*STAR uncovered a key mechanism behind cartilage breakdown and identified new therapeutic targets to slow joint degeneration. 🧠 Clearing Brain Fat to Fight Alzheimer’s: NTU scientists found that reducing lipid buildup in brain immune cells helps them better clear harmful plaques. 🎯 Boosting Immunotherapy with Nanomaterials: Researchers at NTU developed multifunctional palladium-iron nanosheets that supercharge the cancer-immunity cycle and improve T-cell activity in tumors. ❤️ Liver-Brain-Heart Crosstalk in Cardiovascular Disease: NUS researchers discovered that targeting liver-specific SREBP2 significantly reduces cholesterol and atherosclerosis risk, opening up opportunities for inter-organ therapies for heart disease. 🗞️ Wondering what went down in our biohack event, and want to learn about opportunities and events happening in the intersection of AI and drug discovery? check out our event takeaways this month! Read the full issue here 👉 https://lnkd.in/gzZgvgAU Newsletter team: Jiaqi Liang, Senuri De Silva, Damien Chua, Devika Menon Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Shruti Sridhar, Gloria Chan, Isha Karnik, John Joson Ng, Panida Cen, Jashan Singh, Roshni Gupta, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Diya Srivastava, Dijin Zhang, Janelle Low #NucleateSingapore #NucleateArtery 

🧬 Nucleate Ignite Workshop 2: Navigating Clinical Development The second session of the Nucleate Ignite: Biotherapeutic Development Workshop brought participants face-to-face with the intricate process of advancing a therapeutic from target identification through to late-stage clinical trials, with a focus on oncology. Led by Dr. Veronica Diermayr PhD, Asset Development Leader at the Experimental Drug Development Centre (EDDC), the session explored how to build a strategic and comprehensive Clinical Development Plan — from defining the unmet medical need and establishing a Target Product Profile (TPP) to navigating regulatory interactions and designing trials across all phases. Participants gained valuable insights into approaches for biomarker identification, comparisons between traditional and Bayesian trial designs, the rationale behind dose optimization strategies, and regulatory nuances across the US and Singapore. Dr. Diermayr also elaborated on Project Optimus and emphasized the importance of early engagement through Pre-IND and Interact meetings. Real-world examples from antibody-drug conjugate (ADC) programs at EDDC illustrated how complex assets are advanced through global trials, with detailed discussion on risk management strategies, statistical planning, and the construction of a robust trial master file to support regulatory submissions. The evening concluded with an engaging Q&A session with Dr. Diermayr, and included a networking dinner where participants had the opportunity to connect with her and continue meaningful conversations with fellow attendees. We’re excited to see the workshop series come to a close with the final session happening this Tuesday. Stay tuned as we wrap up this journey of translating science into real-world impact! P&E team: Gloria Chan, Panida Cen, Roshni Gupta Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Jiaqi Liang, Damien Chua, Isha Karnik, John Joson Ng, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Senuri De Silva, Diya Srivastava, Dijin Zhang, Devika Menon, Janelle Low #NucleateIgnite #Biotherapeutics #DrugDevelopment #ClinicalTrials #RegulatoryStrategy #BiotechInnovation #TranslationalScience #LifeSciencesLeadership #FromBenchToBedside #NucleateSingapore

A strong IP strategy is fundamental to success in today’s fast-paced biotech landscape. Following his conversation with John Joson Ng for Nucleate Singapore Pulse, we speak to Adam Gregory about crafting effective IP strategies for biotech ventures, avoiding common pitfalls, and adapting to growth and emerging technologies: https://hubs.la/Q03gK8Dz0 #Biotech #MewburnLifeSciences #SingaporeBiotech #IP #LifeSciences #IPStrategy

🚀  Nucleate Ignite Biotherapeutic Development Workshop – Day 1 Day 1 of the Nucleate Ignite Biotherapeutic Development Workshop opened with an insightful session by Dipti Thakkar, who brought deep industry expertise to unpack the journey from scientific discovery to an approved therapeutic. Participants were introduced to the fundamentals of drug development — from pre-discovery and candidate selection, to regulatory strategy and clinical trial design. The session covered how to approach IND filings, what regulators prioritize at different stages, and how to think strategically about data generation and timelines. Attendees also explored the importance of defining a strong Target Product Profile (TPP), the balance between pharmacokinetics (PK) and pharmacodynamics (PD), and how different stakeholders — regulators, investors, and pharma — view risk, novelty, and value. The day included an engaging networking dinner, where participants continued the conversation sharing ideas, discussing challenges in translational research, and getting their questions answered directly by the speaker and peers in an informal setting. And we’re only getting started! Day 2 features hands-on sessions and deeper dives with expert speakers. We look forward to growing this vibrant translational science community together! P&E team: Gloria Chan, Panida Cen, Roshni Gupta Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Jiaqi Liang, Damien Chua, Isha Karnik, John Joson Ng, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Senuri De Silva, Diya Srivastava, Dijin Zhang, Devika Menon, Janelle Low #NucleateIgnite #BiotechInnovation #ClinicalTrials #DrugDevelopment #PharmaStrategy #TranslationalScience #LifeScienceLeadership #FromBenchToBedside #BiotechStartups #MedTech #NucleateSingapore

🎙 Nucleate Singapore Pulse 🚀This month, Nucleate sat down with Dr. Ivan Horak, Founder and CEO of Tikva Allocell Pte Ltd., a late preclinical stage biotech company headquartered in Singapore. Tikva Allocell develops off-the-shelf CAR-T therapy using second-generation allogeneic T cells from EBV-positive individuals to target solid tumors like gastric, prostate, and triple-negative breast cancers. 🎧 In this episode, Dr. Horak discusses his extensive experience and insights through his professional journey in the biotech and pharmaceutical industries as a clinician and researcher. He delves into the complexities of developing effective cancer therapies, highlighting challenges posed by cancer’s heterogeneity and resistance mechanisms. He emphasizes the importance of targeting specific molecular pathways and biomarkers to enhance treatment efficacy and explores how advancements in data analytics, biomarker discovery, and AI-driven platforms are revolutionizing drug development. Dr. Horak also underscores the critical role of collaboration between researchers, clinicians, and pharmaceutical companies in driving innovation and accelerating the development of transformative therapies. Listen and follow us on Spotify 👉https://lnkd.in/gqCmVFM2  and Apple Podcasts 👉https://lnkd.in/gn3x-ihk Show notes and transcripts 👉https://lnkd.in/grpAx5yQ Podcast team: John Joson Ng, Hana Maldivita Tambrin, PhD, Dillon Chew, and Aakash Kumar Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Jiaqi Liang, Damien Chua, Gloria Chan, Isha Karnik, Senuri De Silva, Panida Cen, Roshni Gupta, Diya Srivastava, Dijin Zhang, Devika Menon, Janelle Low #Biotech #Therapeutics #Cancer #Oncology #R&D #Nucleate #Podcast

🔬 The Nucleate Artery: Looking back at half a year of breakthroughs! 📰  ICYMI, we're reflecting on the most exciting biotech innovations we've covered over the past six months! Check out the cutting-edge research that’s shaping the future of healthcare and life sciences in Singapore. 🧬 Want to stay youthful? Discover how Duke-NUS scientists are targeting IL-11 and DEAF1 pathways to reverse aging and muscle loss. 🎗 New Frontiers in Cancer Therapy: From gold nanoparticles to magnetic pulses, learn how Singaporean researchers are improving cancer drug delivery and minimising side effects. 🤖 Bio-Inspired Engineering: Did you miss our issues on robots with a 'sense' of touch and batteries made from flies? ⚕️ Metabolic Health: Check out our coverage of diabetic wound-healing nanotech and multi-target glucagon blockade drugs! We’ve picked our favourites - do *you* have a favourite theme or Digestible? Let us know in the comments below! 🗞️ Stay updated with the latest news on the biggest biotech industry updates, new collaborations, and can’t-miss conferences. Read the full issue here 👉https://lnkd.in/gVBCwU2c Newsletter team: Jiaqi Liang, Senuri De Silva, Damien Chua, Devika Menon Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Shruti Sridhar, Gloria Chan, Isha Karnik, John Joson Ng, Panida Cen, Jashan Singh, Roshni Gupta, Hana Maldivita Tambrin, PhD, Dillon Chew, Aakash Kumar, Diya Srivastava, Dijin Zhang, Janelle Low #NucleateSingapore #NucleateArtery 

🚀 Nucleate Ignite: Biotherapeutic Development Workshop – Last Chance to Apply! Applications for our closed-door Biotherapeutic Development workshop series close on 3rd March—this is your final opportunity to apply! Gain exclusive insights from leading industry experts on IND applications, clinical trial planning, and intellectual property strategy. This highly curated session will also provide a chance to network with biotech leaders and connect over food and refreshments after each session. Workshop Series Schedule: 📅 1 April – The IND Application and Target Product Profile 1. Dipti Thakkar (VP, Target Biology & Pharmacology, Hummingbird Bioscience) 2. Carlo Polo (Senior Director, Regulatory Science, Hummingbird Bioscience) 📅 8 April – The Clinical Development Plan and Considerations for Early-Stage Clinical Trials 1. Veronica Diermayr (Director, Asset Lead, Experimental Drug Development Centre) 📅 15 April – Intellectual Property Strategy for Biotherapeutic Companies 1. Adam Gregory (Partner, Patent Attorney, Mewburn Ellis) 2. Thomas Driver (Associate, Patent Attorney, Mewburn Ellis) ⏰ Time: 6:30 - 9:30 PM 📍 Venue: Details will be shared with confirmed participants 🔗 Submit your application before 3rd March: https://lnkd.in/gA9yJCrN A special thanks to Sartorius for supporting this workshop. Don’t miss this opportunity to learn from industry leaders, expand your professional network, and refine your strategy for biotherapeutic success. Apply now before it’s too late! #NucleateIgnite #Biotech #DrugDevelopment #ClinicalTrials #IntellectualProperty #Innovation #NucleateSingapore #Entrepreneurship Ying Tong Yeo Jessie Wong Ling Ai Samantha Wong, PhD Ivan Seah, MBBS/MBA/MPH Gloria Chan Isha Karnik John Joson Ng Panida Cen Roshni Gupta Hana Maldivita Tambrin, PhD Dillon Chew Aakash Kumar Diya Srivastava Dijin Zhang Jiaqi Liang Senuri De Silva Damien Chua Devika Menon Janelle Low